Promising Results With NAV's GBS Vaccine

- A clinical trial with a polysaccharide conjugate vaccine for the prevention of group B streptococcus disease in newborns, young infants and adults, has demonstrated that the vaccine was well-tolerated with minimal reactogenicity and no serious side effects. Antibodies transported across the placenta may also be able to offer protection to premature babies. The technology has been licensed to North American Vaccine from Brigham and Women's Hospital and Harvard University in the USA.